OncoMatch/Clinical Trials/Blood Cancer — Myelodysplastic (MDS)
Blood Cancer — Myelodysplastic (MDS) Clinical Trials
OncoMatch filters Blood Cancer — Myelodysplastic (MDS) trials by the molecular markers that determine eligibility — TP53, SF3B1, ASXL1, DNMT3A, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaBiomarkers tested in Blood Cancer — Myelodysplastic (MDS) trials
These are the molecular markers most commonly required or evaluated in Blood Cancer — Myelodysplastic (MDS) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Blood Cancer — Myelodysplastic (MDS) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Alliance for Clinical Trials in Oncology
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Merck Sharp & Dohme LLC
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Bristol-Myers Squibb
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
Children's Oncology Group
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda
How OncoMatch finds Blood Cancer — Myelodysplastic (MDS) trials for you
AI reads the protocol
Every Blood Cancer — Myelodysplastic (MDS) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Blood Cancer — Myelodysplastic (MDS) and mark your biomarker results — TP53, SF3B1, ASXL1 — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.